THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that the Company’s IND for the U.S. study of its drug Proellex® has become effective on September 10, 2007. The first study conducted under the new IND will be a Phase II trial that will enroll 75 patients at up to 20 clinical sites in the United States.
